Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $6.59 USD
Change Today +0.13 / 2.01%
Volume 39.0K
ORMP On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

oramed pharmaceuticals inc (ORMP) Snapshot

Open
$6.43
Previous Close
$6.46
Day High
$6.80
Day Low
$6.32
52 Week High
08/29/14 - $10.20
52 Week Low
03/18/15 - $3.71
Market Cap
76.1M
Average Volume 10 Days
58.5K
EPS TTM
$-0.67
Shares Outstanding
11.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ORAMED PHARMACEUTICALS INC (ORMP)

oramed pharmaceuticals inc (ORMP) Related Bloomberg News

View More Bloomberg News

oramed pharmaceuticals inc (ORMP) Related Businessweek News

No Related Businessweek News Found

oramed pharmaceuticals inc (ORMP) Details

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule that completed Phase IIa clinical trials for the treatment of diabetes; and ORMD-0901, an analog for GLP-1 gastrointestinal hormone, which is in pre-clinical trials for the treatment of type 2 diabetes. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in Jerusalem, Israel.

oramed pharmaceuticals inc (ORMP) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $381.3K
Chief Financial Officer, Treasurer and Secret...
Total Annual Compensation: $193.8K
Chief Operating Officer and Vice President of...
Total Annual Compensation: $199.2K
Chief Scientific Officer and Director
Total Annual Compensation: $271.3K
Compensation as of Fiscal Year 2014.

oramed pharmaceuticals inc (ORMP) Key Developments

Oramed Pharmaceuticals Agrees to Investment and License Agreement in China with Sinopharm Capital Management Co. Ltd. and Hefei Life Science & Technology Park Investments and Development Co., Ltd

Oramed Pharmaceuticals announced that it agreed to an investment and license agreement in China with Sinopharm Capital Management Co. Ltd. and Hefei Life Science & Technology Park Investments and Development Co. Ltd. for $50 million plus royalty payments. Under the terms of the agreement, Sinopharm and Hefei will acquire a 10% stake in Oramed Pharma for $12 million and exclusive rights for oral insulin capsule ORMD-0801 for $38 million. Of the $38 million, $18 million will be paid once the license agreement is signed and the remaining $20 million will be paid once results are released for Oramed's ongoing Phase IIb trial in the U.S. Sinopharm and Hefei will also pay a 10% royalty on sales.

Oramed Pharmaceuticals Inc. Enrolls First Patient in its Phase IIb Oral Insulin Study

Oramed Pharmaceuticals Inc. announced that the first patient has been screened in the company's phase IIb trial of its oral insulin capsule, ORMD-0801. This U.S. based study will be performed under the active Investigational New Drug (IND) application on file with the U.S. Food and Drug Administration (FDA). The phase IIb study for type 2 diabetes is designed to generate ample data for both safety and efficacy endpoints. The double-blind, randomized study will recruit approximately 180 patients. ORMD-0801 has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment, potentially slowing disease progression and delaying or even eliminating late-stage complications. Orally administered insulin is expected to bring result in enhanced patient compliance. In addition, intestinally absorbed-oral insulin actually mimics insulin's natural location and gradients in the body by first passing through the liver before entering the bloodstream.

Oramed Pharmaceuticals Inc. Submits Protocol to U.S. FDA for its Phase IIb Oral Insulin Study

Oramed Pharmaceuticals Inc. announced that it has submitted the study protocol for the company's Phase IIb trial of ORMD-0801, its oral insulin capsule, to the U.S. Food and Drug Administration (FDA). The submission was made under the company's existing Investigational New Drug (IND) application. The Phase IIb study of ORMD-0801 for type 2 diabetics is designed to generate ample data for both efficacy and safety endpoints. The double-blind, randomized study will recruit approximately 180 patients and has a 28-day treatment period. The study has already received Institutional Review Board (IRB) approval and patient enrollment is expected to start in the short term.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ORMP:US $6.59 USD +0.13

ORMP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abeona Therapeutics Inc $6.45 USD +0.45
View Industry Companies
 

Industry Analysis

ORMP

Industry Average

Valuation ORMP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ORAMED PHARMACEUTICALS INC, please visit www.oramed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.